The combination of LA-12 with TRAIL enhanced the cytotoxic response also in primary human prostate cancer cells, which was documented by an enhanced cleavage of PARP and caspase-8 (Fig 7A and 7B), and caspase-3, -9 (Fig 7A) or percentage of dead cells in annexin V/PI assay (Fig 7B) in drug combination versus individually treated samples of three patients marked as PY001, PY002 and PY005. Here, ANXA5 is linked to prostate cancer.